The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pro Medicus (PME) subsidiary Visage Imaging has signed a $14 million, eight-year contract with the University of Vermont Health Network
  • The contract will see the company’s Visage 7 diagnostic imaging platform implemented across the university’s six hospitals
  • Notably, Visage 7 will be fully deployed in the public cloud
  • Planning for the rollout is set to commence immediately, with initial “go-lives” targeted for the second half of the calendar year
  • Pro Medicus shares are up 1.45 per cent, trading at $41.15 cents each

Pro Medicus’ (PME) wholly owned subsidiary Visage Imaging has signed a $14 million, eight-year contract with the University of Vermont Health Network.

Based on a transactional licensing model, the contract will see the company’s Visage 7 enterprise diagnostic imaging platform implemented across UVM’s six hospitals.

Notably, the University’s medical centre in Burlington, Vermont, is the teaching hospital for The Larner College of Medicine.

Pro Medicus CEO Dr Sam Hupert said the platform would be deployed in the public cloud.

“We continue to build momentum in the market with this, our seventh contract win in a row, adding to other recent major announcements,” Dr Hupert said

“UVM Health Network is the fourth of these to opt for a cloud-based solution, a trend we see increasing rapidly amongst healthcare systems in North America.”

“Visage 7, with its proven cloud-native capability provides us with a significant strategic advantage that enables us to address these opportunities across a growing segment of the market both in North America and other regions.”

Planning for the rollout is set to commence immediately, with initial “go-lives” targeted for the second half of the calendar year.

On the back of the announcement, Pro Medicus shares are trading 1.45 per cent higher at $41.15 cents at 12:34 pm AEST.

PME by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…